多相脂质体139(以下简称139)对肺癌患者巨噬细胞趋化和游移功能有明显的促进和保护作用。单用139组中69％患者该功能平均提高1倍,而单用化疗组有75％患者该功能受到明显的损害。如先用139 1～2周再用化疗,则有70％患者该功能受到明显的保护。因此。认为139可成为一新型的抗肿瘤免疫增强剂。 Polyphasic liposomes 139 (hereinafter referred to as 139) significantly promoted and protected macrophages from chemotaxis and migration in lung cancer patients. This function was increased by a factor of 2 on average in 69% of patients in the 139 group alone, and was significantly impaired in 75% of patients treated with chemotherapy alone. If chemotherapies were first used in 139 1 to 2 weeks, 70% of patients were clearly protected. therefore. It is believed that 139 can become a new type of anti-tumor immune enhancer.